ERBB2 and breast cancer: Our data suggest the importance of chemotherapy-induced alterations in m6A modifications and the protective role of METTL3 in HR+HER2− subtype BC, providing a theoretical basis for METTL3 as a new predictor of chemotherapy response and target for drug therapy.